BioCentury | Mar 17, 2021
Management Tracks

High-profile departures at Sage, bluebird as Cloonan, Davidson depart; plus CBC Group, Turning Point, Agilent, Intercept, Centessa, Beam and more

...Perlmutter as science partner and a member of scientific board. Yi Larson is resigning as CFO of Turning Point Therapeutics Inc. (NASDAQ:TPTX...
...was EVP of legal and general counsel at Sarepta Therapeutics Inc. (NASDAQ:SRPT). Gunjan Ohri Agilent Technologies Inc. Turning Point Therapeutics Inc. Moderna...
BioCentury | Mar 5, 2021
Deals

March 4 Quick Takes: Crossovers pour into Amunix’s $117M B round; plus funding for atai, BlossomHill, OnKure, Exscientia, CorVista, Blue Note and Geneos and deals for Takeda-Enzyre, ConserV-eTheRNA

...small molecule discovery and development company with Y. Peter Li.; the duo also founded Turning Point Therapeutics Inc....
BioCentury | Jan 12, 2021
Deals

Jan. 11 Quick Takes: Inmagene gains options to four Chi-Med immunology programs; plus Zai-Turning Point, Mirati-Resolution, GSK-Eligo, Biogen-Apple, Adaptive-AZ and more

...development.Zai Lab adds another Turning Point program to stable of targeted oncology assetsOn Monday Turning Point Therapeutics Inc....
...Bioscience Inc. Verily Life Sciences LLC Broad Institute of MIT and Harvard Microsoft Corp. Taizhou EOC Pharma Co. Ltd. Turning Point Therapeutics Inc. AstraZeneca...
BioCentury | Oct 28, 2020
Finance

Oct. 27 Financial Quick Takes: Apellis-Sobi deal for C3 inhibitor; plus Primmune, Prokarium, Novartis-RegenxBio, Turning Point, Psyomics, Journey Colab

...abeparvovec-xioi, which uses RegenXBio’s proprietary NAV AAV9 vector.Turning Point prices $400M follow-onPrecision oncology company Turning Point Therapeutics Inc....
...– Complement 3TLR7 – Toll-like receptor 7 Paul Bonanos Apellis Pharmaceuticals Inc. Swedish Orphan Biovitrum AB Prokarium Ltd. RegenxBio Inc. Turning Point Therapeutics Inc. Primmune...
BioCentury | Oct 7, 2020
Finance

With life sciences now a ‘core’ investment area, General Atlantic picks a global head

...been since 2015. He held board seats or was an observer at companies including Turning Point Therapeutics Inc....
BioCentury | Jul 16, 2020
Management Tracks

NextCure CMO Heller to resign; plus Vertex, Turning Point, Scholar Rock, C4, Vor and more

...combination therapy (see “Vertex, NHS in Deal for CF Triplet” ). Precision oncology company Turning Point Therapeutics Inc....
...Pharmaceuticals Inc. C4 Therapeutics Inc. Scholar Rock Holding Corp. Vor Biopharma Inc. Autobahn Therapeutics Inc. Cerevel Therapeutics Holdings Inc. NextCure Inc. Turning Point Therapeutics Inc. Phathom...
BioCentury | Jul 7, 2020
Deals

Adding to targeted oncology portfolio, Zai gains China rights to Turning Point’s repotrectinib

...China to repotrectinib, a small molecule inhibitor of ALK, ROS1, TrkA, TrkB and TrkC. Turning Point Therapeutics Inc....
...kinase receptor 2 TrkC (NTRK3) - Neurotrophic tyrosine kinase receptor 3 Paul Bonanos, Associate Editor repotrectinib (TPX-0005) Turning Point Therapeutics Inc. Zai...
BioCentury | Feb 22, 2020
Management Tracks

Everest names new CEO; plus Merck, Gilead, Turning Point, Adaptimmune, AskBio and more

...plans to appoint Deputy Chairman Deirdre Connelly as the new chairman. Precision oncology company Turning Point Therapeutics Inc....
BioCentury | Jan 11, 2020
Company News

Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more

...Ventures and Lilly Asia Ventures (see “Lilly to Acquire Loxo” ). Precision oncology company Turning Point Therapeutics Inc....
...Avidity Biosciences LLC. BioCentury Staff Impel NeuroPharma Inc. Candel Therapeutics Relmada Therapeutics Inc. Wave Life Sciences Ltd. Boston Therapeutics Inc. Polaris Partners Turning Point Therapeutics Inc. TauC3...
BioCentury | Jan 7, 2020
Company News

Management tracks: New director for CMS’s CMMI, plus FibroGen, Turning Point, Akcea, Antengene, Biocon and more

...passing of Tom Neff, becomes chairman (see “FibroGen’s Neff Passes Away” ). Cancer company Turning Point Therapeutics Inc....
...Inc. Arrowhead Pharmaceuticals Inc. Kura Oncology Inc. Biocon Ltd. DeepBiome Therapeutics Inc. FibroGen Inc. Antengene Corp. Ltd. Akcea Therapeutics Inc. Carisma Therapeutics Inc. Turning Point Therapeutics Inc. Phathom...
Items per page:
1 - 10 of 113
BioCentury | Mar 17, 2021
Management Tracks

High-profile departures at Sage, bluebird as Cloonan, Davidson depart; plus CBC Group, Turning Point, Agilent, Intercept, Centessa, Beam and more

...Perlmutter as science partner and a member of scientific board. Yi Larson is resigning as CFO of Turning Point Therapeutics Inc. (NASDAQ:TPTX...
...was EVP of legal and general counsel at Sarepta Therapeutics Inc. (NASDAQ:SRPT). Gunjan Ohri Agilent Technologies Inc. Turning Point Therapeutics Inc. Moderna...
BioCentury | Mar 5, 2021
Deals

March 4 Quick Takes: Crossovers pour into Amunix’s $117M B round; plus funding for atai, BlossomHill, OnKure, Exscientia, CorVista, Blue Note and Geneos and deals for Takeda-Enzyre, ConserV-eTheRNA

...small molecule discovery and development company with Y. Peter Li.; the duo also founded Turning Point Therapeutics Inc....
BioCentury | Jan 12, 2021
Deals

Jan. 11 Quick Takes: Inmagene gains options to four Chi-Med immunology programs; plus Zai-Turning Point, Mirati-Resolution, GSK-Eligo, Biogen-Apple, Adaptive-AZ and more

...development.Zai Lab adds another Turning Point program to stable of targeted oncology assetsOn Monday Turning Point Therapeutics Inc....
...Bioscience Inc. Verily Life Sciences LLC Broad Institute of MIT and Harvard Microsoft Corp. Taizhou EOC Pharma Co. Ltd. Turning Point Therapeutics Inc. AstraZeneca...
BioCentury | Oct 28, 2020
Finance

Oct. 27 Financial Quick Takes: Apellis-Sobi deal for C3 inhibitor; plus Primmune, Prokarium, Novartis-RegenxBio, Turning Point, Psyomics, Journey Colab

...abeparvovec-xioi, which uses RegenXBio’s proprietary NAV AAV9 vector.Turning Point prices $400M follow-onPrecision oncology company Turning Point Therapeutics Inc....
...– Complement 3TLR7 – Toll-like receptor 7 Paul Bonanos Apellis Pharmaceuticals Inc. Swedish Orphan Biovitrum AB Prokarium Ltd. RegenxBio Inc. Turning Point Therapeutics Inc. Primmune...
BioCentury | Oct 7, 2020
Finance

With life sciences now a ‘core’ investment area, General Atlantic picks a global head

...been since 2015. He held board seats or was an observer at companies including Turning Point Therapeutics Inc....
BioCentury | Jul 16, 2020
Management Tracks

NextCure CMO Heller to resign; plus Vertex, Turning Point, Scholar Rock, C4, Vor and more

...combination therapy (see “Vertex, NHS in Deal for CF Triplet” ). Precision oncology company Turning Point Therapeutics Inc....
...Pharmaceuticals Inc. C4 Therapeutics Inc. Scholar Rock Holding Corp. Vor Biopharma Inc. Autobahn Therapeutics Inc. Cerevel Therapeutics Holdings Inc. NextCure Inc. Turning Point Therapeutics Inc. Phathom...
BioCentury | Jul 7, 2020
Deals

Adding to targeted oncology portfolio, Zai gains China rights to Turning Point’s repotrectinib

...China to repotrectinib, a small molecule inhibitor of ALK, ROS1, TrkA, TrkB and TrkC. Turning Point Therapeutics Inc....
...kinase receptor 2 TrkC (NTRK3) - Neurotrophic tyrosine kinase receptor 3 Paul Bonanos, Associate Editor repotrectinib (TPX-0005) Turning Point Therapeutics Inc. Zai...
BioCentury | Feb 22, 2020
Management Tracks

Everest names new CEO; plus Merck, Gilead, Turning Point, Adaptimmune, AskBio and more

...plans to appoint Deputy Chairman Deirdre Connelly as the new chairman. Precision oncology company Turning Point Therapeutics Inc....
BioCentury | Jan 11, 2020
Company News

Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more

...Ventures and Lilly Asia Ventures (see “Lilly to Acquire Loxo” ). Precision oncology company Turning Point Therapeutics Inc....
...Avidity Biosciences LLC. BioCentury Staff Impel NeuroPharma Inc. Candel Therapeutics Relmada Therapeutics Inc. Wave Life Sciences Ltd. Boston Therapeutics Inc. Polaris Partners Turning Point Therapeutics Inc. TauC3...
BioCentury | Jan 7, 2020
Company News

Management tracks: New director for CMS’s CMMI, plus FibroGen, Turning Point, Akcea, Antengene, Biocon and more

...passing of Tom Neff, becomes chairman (see “FibroGen’s Neff Passes Away” ). Cancer company Turning Point Therapeutics Inc....
...Inc. Arrowhead Pharmaceuticals Inc. Kura Oncology Inc. Biocon Ltd. DeepBiome Therapeutics Inc. FibroGen Inc. Antengene Corp. Ltd. Akcea Therapeutics Inc. Carisma Therapeutics Inc. Turning Point Therapeutics Inc. Phathom...
Items per page:
1 - 10 of 113